We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Distinguishes between Forms of Inflammatory Bowel Disease

By LabMedica International staff writers
Posted on 13 May 2019
Print article
Image: A micrograph of a colonic biopsy showing inflammation of the large bowel in a case of inflammatory bowel disease (Photo courtesy of Wikimedia Commons).
Image: A micrograph of a colonic biopsy showing inflammation of the large bowel in a case of inflammatory bowel disease (Photo courtesy of Wikimedia Commons).
A recently developed blood test distinguishes between mild and severe forms of inflammatory bowel disease and is potentially a step towards realizing personalized therapy for the syndrome.

Crohn's disease and ulcerative colitis, collectively referred to as inflammatory bowel disease (IBD), are chronic conditions that involve inflammation of the gut. Investigators at the University of Cambridge (United Kingdom) had previously described a prognostic transcriptional signature in CD8 T-cells that separated patients with IBD into two phenotypically distinct subgroups, termed IBD1 and IBD2. The IBD1 subgroup experienced significantly more aggressive disease and demonstrated poorer prognosis than IBD2 patients.

In the current study, the investigators sought to develop a blood-based test that could identify these subgroups without cell separation and be suitable for clinical use. To this end, they used a combination of machine learning and the qPCR (quantitative polymerase chain reaction) whole blood assay to identify genetic signatures in a cohort of 69 Crohn's disease patients that re-created the two subgroups from their previous study. The signatures were then validated in 123 IBD patients. Results indicated that the new test was 90-100% accurate in correctly identifying patients with the milder IBD2 form of the disease.

"IBD can be a very debilitating disease, but this new test could help us transform treatment options, moving away from a "one size fits all" approach to a personalized approach to treating patients," said senior author Dr. Kenneth G. C. Smith, professor of medicine at the University of Cambridge.

Further development of the test is being carried out by the spinout company PredictImmune (Cambridge, United Kingdom).

The IBD blood test was described in the April 27, 2019, online edition of the journal Gut.

Related Links:
University of Cambridge
PredictImmune

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.